Free Cash Flow per Share: A measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Calculated as: Free Cash Flow / Weighted Average Shares Outstanding (Diluted)
Cullinan Therapeutics, Inc. (CGEM) had Free Cash Flow per Share of $-2.70 for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-167.38M |
|
-- |
|
-- |
|
$196.92M |
|
$-196.92M |
|
$29.46M |
|
$-167.46M |
|
$-167.46M |
|
$-167.57M |
|
$-167.57M |
|
$-167.57M |
|
$-167.57M |
|
$-196.92M |
|
$-196.61M |
|
53.77M |
|
53.77M |
|
$-2.78 |
|
$-2.78 |
|
| Balance Sheet Financials | |
$414.67M |
|
$0.68M |
|
$207.16M |
|
$621.82M |
|
$30.65M |
|
-- |
|
$0.85M |
|
$31.50M |
|
$590.33M |
|
$590.33M |
|
$590.33M |
|
58.51M |
|
| Cash Flow Statement Financials | |
$-145.30M |
|
$-136.31M |
|
$266.19M |
|
$98.43M |
|
$83.00M |
|
$-15.43M |
|
$37.82M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
13.53 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-145.30M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-28.39% |
|
-28.39% |
|
-26.95% |
|
-28.39% |
|
$10.09 |
|
|
Free Cash Flow per Share |
$-2.70 |
$-2.70 |
|